Cogent Biosciences, Inc. (COGT): Price and Financial Metrics
COGT Price/Volume Stats
| Current price | $7.53 | 52-week high | $13.50 |
| Prev. close | $7.29 | 52-week low | $3.67 |
| Day low | $7.33 | Volume | 846,300 |
| Day high | $7.72 | Avg. volume | 1,988,500 |
| 50-day MA | $6.75 | Dividend yield | N/A |
| 200-day MA | $8.13 | Market Cap | 719.97M |
COGT Stock Price Chart Interactive Chart >
Cogent Biosciences, Inc. (COGT) Company Bio
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a Âbolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Latest COGT News From Around the Web
Below are the latest news stories about COGENT BIOSCIENCES INC that investors may wish to consider to help them evaluate COGT as an investment opportunity.
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose Nearly all patients achieved at least 50% improvement in key biomarkers of disease burden: serum tryptase reduction (94%), KIT D816V VAF reduction (93%), and bone marrow mast cell burden (97%) Encouraging safety and tolerability profile with no related cognitive impairment or bleeding events reported Cogent to host investor webcast to |
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated patients achieved at least 50% improvement across all relevant biomarker measures, including serum tryptase, KIT D816V VAF, and mast cell burden; Placebo patients, after cross-over to bezuclastinib, also demonstrated rapid symptomatic improvement, with 75% median best improvement on MC-QoL, and 67% of pat |
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer SymposiumNovel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently approved therapies Novel, H1047R mutant-selective PI3Kα inhibitor, disclosed as third Cogent discovery stage program, demonstrates high clinical target engagement without metabolic dysfunction commonly associated with molecules in the class WALTHAM, Mass. and BOULDER, Colo., Dec. 07, 2023 (GLOBE NEWSWIRE |
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Additional clinical data update from APEX Part 1 in patients with Advanced Systemic Mastocytosis (AdvSM) also to be reviewed WALTHAM, Mass. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its invest |
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer SymposiumWALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster presentations at the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2023 at the Henry B. González Convention Center in San Antonio, Texas. Poster DetailsThe posters will be available on the ‘Posters and Publications’ page of |
COGT Price Returns
| 1-mo | 9.13% |
| 3-mo | 56.88% |
| 6-mo | -9.82% |
| 1-year | -32.89% |
| 3-year | -8.17% |
| 5-year | N/A |
| YTD | 28.06% |
| 2023 | -49.13% |
| 2022 | 34.73% |
| 2021 | -23.60% |
| 2020 | 289.82% |
| 2019 | N/A |
Loading social stream, please wait...